XBP1型
生物
免疫系统
未折叠蛋白反应
内质网
免疫
癌症研究
树突状细胞
免疫学
平衡
下调和上调
癌症
基因沉默
细胞生物学
生物化学
核糖核酸
遗传学
RNA剪接
基因
作者
Juan R. Cubillos‐Ruiz,Pedro C. Silberman,Melanie R. Rutkowski,Sahil Chopra,Alfredo Perales‐Puchalt,Minkyung Song,Sheng Zhang,Sarah E. Bettigole,Divya Gupta,Kevin Holcomb,Benjamin D. Cosgrove,Thomas A. Caputo,Ann–Hwee Lee,José R. Conejo-García,Laurie H. Glimcher
出处
期刊:Cell
[Elsevier]
日期:2015-06-01
卷期号:161 (7): 1527-1538
被引量:695
标识
DOI:10.1016/j.cell.2015.05.025
摘要
Dendritic cells (DCs) are required to initiate and sustain T cell-dependent anti-cancer immunity. However, tumors often evade immune control by crippling normal DC function. The endoplasmic reticulum (ER) stress response factor XBP1 promotes intrinsic tumor growth directly, but whether it also regulates the host anti-tumor immune response is not known. Here we show that constitutive activation of XBP1 in tumor-associated DCs (tDCs) drives ovarian cancer (OvCa) progression by blunting anti-tumor immunity. XBP1 activation, fueled by lipid peroxidation byproducts, induced a triglyceride biosynthetic program in tDCs leading to abnormal lipid accumulation and subsequent inhibition of tDC capacity to support anti-tumor T cells. Accordingly, DC-specific XBP1 deletion or selective nanoparticle-mediated XBP1 silencing in tDCs restored their immunostimulatory activity in situ and extended survival by evoking protective type 1 anti-tumor responses. Targeting the ER stress response should concomitantly inhibit tumor growth and enhance anti-cancer immunity, thus offering a unique approach to cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI